Redx Pharma Announces First Patient Dosed in Phase 1/2a

Redx Pharma has commenced a Phase I study for a novel cancer treatment at The Christie in Manchester.

The compound, RXC004, is a novel, oral, potent small molecule Porcupine inhibitor, and targets the Wnt pathway that is implicated in the maintenance of cancer stem cells.

ApconiX were proud to work with our Redx colleagues in reaching this important milestone, by providing support in drug project toxicology.

By |2018-07-11T12:18:33+00:00February 13th, 2018|Toxicology|Comments Off on Redx Pharma Announces First Patient Dosed in Phase 1/2a

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.